menu ☰
menu ˟

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271)

Creator:

National Institute for Health and Clinical Excellence (NICE)

Subject Keywords: Diabetes
Set: Obesity
Type: Guideline
Region: United Kingdom
Description:

Fluocinolone acetonide intravitreal implants are recommended as a possible treatment for people with chronic diabetic macular oedema who have an artificial lens in their eye if:

  • the implant is used in the eye with the artificial lens and
  • their diabetic macular oedema has not got better with other treatments.

This guidance replaces NICE technology appraisal guidance 271 (published January 2013). TA271 did not recommend fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema considered insufficiently responsive to available therapies. The updated guidance recommends fluocinolone acetonide intravitreal implant as an option for treating chronic diabetic macular oedema that is insufficiently responsive to available therapies only if the implant is to be used in an eye with an intraocular (pseudophakic) lens and the manufacturer provides fluocinolone acetonide intravitreal implant with the discount agreed in the patient access scheme.

Date:

27/11/2013

Rights: © NICE
Suggested citation:

National Institute for Health and Clinical Excellence (NICE). (2013) Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271) [Online]. Available from: http://www.thehealthwell.info/node/668169 [Accessed: 17th November 2017].

  

View your saved citations and reading lists

Contributor:

Other partner websites
 
Click here to view all the resources gathered from this organisation's website.